PharmaPoint: Hemophilia A and B – France Drug Forecast and Market Analysis to 2022, New Report Launched

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

The primary research indicates that the high annual cost of therapy in France is of great concern among French physicians and regulators and therefore the opportunities for premium pricing for new therapies will be limited during the forecast period. GlobalData believes that the clinical benefits offered by the emerging long-acting replacement factors will be sufficient to allow companies to negotiate modest price premiums for the long-acting therapies.

 Scope

  • Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in France from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting France Hemophilia A and B market.
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in France

 Spanning over 137 pages, 52 Tables and 3 Figures, PharmaPoint: Hemophilia A and B – France Drug Forecast and Market Analysis to 2022 report covering Disease Overview, Disease Management, Competitive Assessment, Opportunity and Unmet Need, Pipeline Assessment, Market Outlook, Appendix.

Inquire about this report: http://www.marketresearchreports.com/globaldata/pharmapoint-hemophilia-and-b-france-drug-forecast-and-market-analysis-2022

Browse more Diseases Reports at: http://www.marketresearchreports.com/diseases

About Market Research Reports, Inc.

MarketResearch Reports, Inc.is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

PharmaPoint: Atopic Dermatitis – Japan Drug Forecast and Market Analysis to 2022, New Report Launched

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

 By the mid-to-late term of Publisher’s 2012 to 2022 forecast, Sanofi/Regeneron’s dupilumab is expected to reshape the moderate and severe treatment landscape.

Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.

Growth within that market will stem from the positive uptake of three therapies: cyclosporine, systemic antihistamines and the Japanese-manufactured topical calcineurin inhibitor, Astellas/Maruho’s Protopic. Collectively, these three therapies will contribute $361.9m sales to the 2022.

Scope

  • Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting Japan Atopic Dermatitis market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Japan

Spanning over 99 pages, 27 Tables and 4 Figures, PharmaPoint: Atopic Dermatitis – Japan Drug Forecast and Market Analysis to 2022 report covering Disease Overview, Disease Management, Competitive Assessment, Opportunity and Unmet Need, Pipeline Assessment, Market Outlook, Appendix.

Inquire about this report: http://www.marketresearchreports.com/globaldata/pharmapoint-atopic-dermatitis-japan-drug-forecast-and-market-analysis-2022

Browse more Healthcare reports at: http://www.marketresearchreports.com/healthcare

About Market Research Reports, Inc.

MarketResearch Reports, Inc. (www.MarketResearchReports.com) is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

PharmaPoint: Atopic Dermatitis – India Drug Forecast and Market Analysis to 2022

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

 By the mid-to-late term of Publisher’s 2012 to 2022 forecast, Sanofi/Regeneron’s dupilumab is expected to reshape the moderate and severe treatment landscape.

Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.

Strong uptake of branded and generic topical calcineurin inhibitors as well as systemic vitamin derivatives will be the key growth drivers, while prescribing behavior of Indian dermatologists from GlobalData’s July 2013 survey suggests a highly crowded, genericized market.

 Scope

  •  Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  •  Detailed information on the key drugs in India including product description, safety and efficacy profiles as well as a SWOT analysis.
  •  Sales forecast for the top drugs in India from 2012-2022.
  •  Analysis of the impact of key events as well the drivers and restraints affecting India Atopic Dermatitis market.

 Reasons to buy

  •  Understand and capitalize by identifying products that are most likely to ensure a robust return
  •  Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis
  •  Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  •  Make more informed business decisions from insightful and in-depth analysis of drug performance
  •  Obtain sales forecast for drugs from 2012-2022 in India.

 Spanning over 95 pages, 25 Tables and 4 Figures, PharmaPoint: Atopic Dermatitis – India Drug Forecast and Market Analysis to 2022 report covering Disease Overview, Disease Management, Competitive Assessment, Opportunity and Unmet Need, Pipeline Assessment, Market Outlook, Appendix.

Inquire about this report: http://www.marketresearchreports.com/globaldata/pharmapoint-atopic-dermatitis-india-drug-forecast-and-market-analysis-2022

 Browse more Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

About Market Research Reports, Inc.

Market Research Reports, Inc.  is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

 For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

PharmaPoint: Atopic Dermatitis – China Drug Forecast and Market Analysis to 2022, New Report Launched

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.By the mid-to-late term of Publisher’s 2012 to 2022 forecast, Sanofi/Regeneron’s dupilumab is expected to reshape the moderate and severe treatment landscape.

Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.

publisher attributes this to the low drug treatment rates in that market, which lower the aforementioned patient pool to 3.3 million, and also because that market is saturated with generic topical therapies. Nonetheless, similar market dynamics to that of the 7MM are at play in the Chinese market, in that topical corticosteroids and moisturizers/emollients dominate the treatment landscape, with 60%–90% of patients across all severities receiving these therapies.

 Scope

  • Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in China from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting China Atopic Dermatitis market.
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in China

Reasons to buy 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  •  Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis
  •  Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  •  Make more informed business decisions from insightful and in-depth analysis of drug performance
  •  Obtain sales forecast for drugs from 2012-2022 in China

Spanning over 87 pages, 23 Tables and 4 Figures, PharmaPoint: Atopic Dermatitis – China Drug Forecast and Market Analysis to 2022 report covering Disease Overview, Disease Management, Competitive Assessment, Opportunity and Unmet Need, Pipeline Assessment, Market Outlook, Appendix.

Inquire about this report: http://www.marketresearchreports.com/globaldata/pharmapoint-atopic-dermatitis-china-drug-forecast-and-market-analysis-2022

 Browse more Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

PharmaPoint: Atopic Dermatitis – Spain Drug Forecast and Market Analysis to 2022, New Report Launched

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

By the mid-to-late term of Publisher’s 2012 to 2022 forecast, Sanofi/Regeneron’s dupilumab is expected to reshape the moderate and severe treatment landscape.

Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.

Based on Publisher’s July 2013 survey data, the key growth drivers in Spain in the near term will be systemic products, particularly those within the antibiotics class, and off-label therapies Xolair and Actimmune. The anticipated uptake of these off-label therapies will be most prominent in patients with severe disease. Another important growth driver will be increasing uptake of the topical calcineurin inhibitor brand Elidel.

Scope

  • Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Spain from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting Spain Atopic Dermatitis market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Spain

Spanning over 104 pages, 30 Tables and 4 Figures, PharmaPoint: Atopic Dermatitis – Spain Drug Forecast and Market Analysis to 2022” report covering the Disease Overview, Disease Management, Competitive Assessment, Opportunity and Unmet Need, Pipeline Assessment, Market Outlook, Appendix.

Inquire about this report: http://www.marketresearchreports.com/globaldata/pharmapoint-atopic-dermatitis-spain-drug-forecast-and-market-analysis-2022

About Market Research Reports, Inc.

Market Research Reports,Inc. (www.MarketResearchReports.com) is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

PharmaPoint: Atopic Dermatitis – Germany Drug Forecast and Market Analysis to 2022, New Report Launched

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

By the mid-to-late term of Publisher’s 2012 to 2022 forecast, Sanofi/Regeneron’s dupilumab is expected to reshape the moderate and severe treatment landscape.

Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.

Growth within the German atopic dermatitis market is attributed to the anticipated rise in prescriptions for systemic therapies, in particular methotrexate, mycophenolate mofetil and off-label biologic Xolair, as well as the high annual cost of current therapies relative to other EU countries. These expectations are the key drivers that will allow Germany to maintain a solid position.

Scope

  • Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Germany including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Germany from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting Germany Atopic Dermatitis market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Germany

Spanning over 116 pages, 34 Tables and 42 Figures, PharmaPoint: Atopic Dermatitis – Germany Drug Forecast and Market Analysis to 2022” report covering Disease Overview, Disease Management, Competitive Assessment, Opportunity and Unmet Need, Pipeline Assessment, Market Outlook, Appendix.

Inquire about this report: http://www.marketresearchreports.com/globaldata/pharmapoint-atopic-dermatitis-germany-drug-forecast-and-market-analysis-2022

About Market Research Reports, Inc.

Market Research Reports,Inc. (www.MarketResearchReports.com) is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

PharmaPoint: Atopic Dermatitis – Current and Future Players, New Report Launched

PharmaPoint: Atopic Dermatitis – Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Atopic Dermatitis Market. The report identifies and analyses the key companies shaping and driving the global Atopic Dermatitis market. The report provides insight into the competitive Atopic Dermatitis landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

Scope

  • Investigation of current and future market competition for Atopic Dermatitis
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of the Atopic Dermatitis sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving the Atopic Dermatitis Market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What’s the next big thing in the global Atopic Dermatitis market landscape? Identify, understand and capitalize

Spanning over 46 pages, 12 Tables and 2 Figures, PharmaPoint: Atopic Dermatitis – Current and Future Players report covering Introduction, Market Outlook, Current and Future Players, Appendix. The report covering 4 companies- Astellas, Meda, Regeneron, Anacor.

Inquire about this report: http://www.marketresearchreports.com/globaldata/pharmapoint-atopic-dermatitis-current-and-future-players

About Market Research Reports, Inc.

Market Research Reports,Inc. (www.MarketResearchReports.com) is the world’s leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter